Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 9

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 included in raw materials and work in progress inventory. We classify inventory that we do not expect to utilize within 12 months of the balance sheet date as “strategic inventory,” a non-current asset.Prepaid expenses and other current assetsSeptember 30,2025December 31,2024(in thousands)Prepaid expenses$22,981 $9,492 Deferred clinical materials6,010 4,493 Clinical deposits2,479 1,817 Other current assets5,999 6,078 Total prepaid expenses and other current assets$37,469 $21,880 As of September 30, 2025 and December 31, 2024, prepaid expenses included $14.2 million and $3.8 million of prepaid taxes, respectively.

11

Accrued and other liabilitiesSeptember 30,2025December 31,2024 (in thousands)Government rebates$53,335 $41,580 Accrued compensation35,284 41,731 Accrued selling and marketing costs8,918 3,345 Other10,910 4,044 Total accrued and other liabilities$108,447 $90,700 

3. Available-for-Sale Marketable Securities and Fair Value Measurements

The available-for-sale securities in our condensed consolidated balance sheets are as follows:September 30,2025December 31,2024(in thousands)Cash equivalents$100,392 $98,436 Short-term marketable securities296,544 255,669 Long-term marketable securities102,557 219,831 Total marketable securities$499,493 $573,936 The following table presents our available-for-sale securities grouped by asset type: Fair ValueHierarchyLevelSeptember 30, 2025December 31, 2024Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value  (in thousands)Corporate bondsLevel 2$324,328 $843 $(12)$325,159 $373,440 $333 $(529)$373,244 Commercial paperLevel 26,982 — — 6,982 9,771 6 (2)9,775 U.S. government agency securitiesLevel 226,998 4 — 27,002 7,999